Evaluation of the stability of enterovirus 71 virus-like particle

Journal of Bioscience and Bioengineering

Volumn 117, Issue 3, 2014, Pages 366-371

  Lin, Shih Yeh ^a   Chung, Yao Chi ^b   Chiu, Hsin Yi ^a   Chi, Wei Kuang ^c   Chiang, Bor Luen ^d   Hu, Yu Chen ^a  

^a NATIONAL TSING HUA UNIVERSITY   (Taiwan)

^b NATIONAL PINGTUNG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^c DEVELOPMENT CENTER FOR BIOTECHNOLOGY   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Baculovirus; Enterovirus 71; Insect cell; Stability; Virus like particle

Indexed keywords

BACULOVIRUS; ENTEROVIRUS 71; INSECT CELL; STABILITY; VIRUS-LIKE PARTICLE;

ANIMALS; ANTIBODIES, VIRAL; CELL LINE; ENTEROVIRUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; INSECTS; MICROSCOPY, ELECTRON, TRANSMISSION; PARTICLE SIZE; PROTEIN STABILITY; SODIUM CHLORIDE; VACCINES, VIRUS-LIKE PARTICLE; VIRAL STRUCTURAL PROTEINS; VIRAL VACCINES;

EID: 84893798501     PISSN: 13891723     EISSN: 13474421     Source Type: Journal    
DOI: 10.1016/j.jbiosc.2013.08.015     Document Type: Article

References (38)

1. Bek E.J., McMinn P.C. Recent advances in research on human enterovirus 71. Future Virol. 2010, 5:453-468.
2. Wang X., Peng W., Ren J., Hu Z., Xu J., Lou Z., Li X., Yin W., Shen X., Porta C., other 3 authors Asensor-adaptor mechanism for enterovirus uncoating from structures of EV71. Nat. Struct. Mol. Biol. 2012, 19:424-429.
3. Plevka P., Perera R., Cardosa J., Kuhn R.J., Rossmann M.G. Crystal structure of human enterovirus 71. Science 2012, 336:1274.
4. Lee M.S., Chang L.Y. Development of enterovirus 71 vaccines. Expert Rev. Vaccines 2010, 9:149-156.
5. McMinn P.C. An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS Microbiol. Rev. 2002, 26:91-107.
6. Chong P., Hsieh S.Y., Liu C.C., Chou A.H., Chang J.Y., Wu S.C., Liu S.J., Chow Y.H., Su I.J., Klein M. Production of EV71 vaccine candidates. Hum. Vaccin. Immunother. 2012, 8:1775-1783.
7. Fujimoto T., Chikahira M., Yoshida S., Ebira H., Hasegawa A., Totsuka A., Nishio O. Outbreak of central nervous system disease associated with hand, foot, and mouth disease in Japan during the summer of 2000: detection and molecular epidemiology of enterovirus 71. Microbiol. Immunol. 2002, 46:621-627.
8. Solomon T., Lewthwaite P., Perera D., Cardoso M.J., McMinn P., Ooi M.H. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect. Dis. 2010, 10:778-790.
9. Tee K.K., Lam T.T.Y., Chan Y.F., Bible J.M., Kamarulzaman A., Tong C.Y.W., Takebe Y., Pybus O.G. Evolutionary genetics of human enterovirus 71: origin, population dynamics, natural selection, and seasonal periodicity of the VP1 gene. J.Virol. 2010, 84:3339-3350.
10. Lin T.Y., Twu S.J., Ho M.S., Chang L.Y., Lee C.Y. Enterovirus 71 outbreaks, Taiwan: occurrence and recognition. Emerg. Infect. Dis. 2003, 9:291-293.
11. Ong K.C., Devi S., Cardosa M.J., Wong K.T. Formaldehyde-inactivated whole-virus vaccine protects a murine model of enterovirus 71 encephalomyelitis against disease. J.Virol. 2010, 84:661-665.
12. Liu L., Zhang Y., Wang J., Zhao H., Jiang L., Che Y., Shi H., Li R., Mo Z., Huang T., other 3 authors Study of the integrated immune response induced by an inactivated EV71 vaccine. PLoS One 2013, 8:e54451.
13. Chen C.W., Lee Y.P., Wang Y.F., Yu C.K. Formaldehyde-inactivated human enterovirus 71 vaccine is compatible for co-immunization with a commercial pentavalent vaccine. Vaccine 2011, 29:2772-2776.
14. Chen H.L., Huang J.Y., Chu T.W., Tsai T.C., Hung C.M., Lin C.C., Liu F.C., Wang L.C., Chen Y.J., Lin M.F., Chen C.M. Expression of VP1 protein in the milk of transgenic mice: a potential oral vaccine protects against enterovirus 71 infection. Vaccine 2008, 26:2882-2889.
15. Chung Y.-C., Ho M.-S., Wu J.-C., Chen W.-J., Huang J.-H., Chou S.-T., Hu Y.-C. Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge. Vaccine 2008, 26:1855-1862.
16. Lin Y.L., Yu C.I., Hu Y.C., Tsai T.J., Kuo Y.C., Chi W.K., Lin A.N., Chiang B.L. Enterovirus type 71 neutralizing antibodies in the serum of macaque monkeys immunized with EV71 virus-like particles. Vaccine 2012, 30:1305-1312.
17. Bek E.J., Hussain K.M., Phuektes P., Kok C.C., Gao Q., Cai F., Gao Z.L., McMinn P.C. Formalin-inactivated vaccine provokes cross-protective immunity in a mouse model of human enterovirus 71 infection. Vaccine 2011, 29:4829-4838.
18. Zhu F.-C., Liang Z.-L., Li X.-L., Ge H.-M., Meng F.-Y., Mao Q.-Y., Zhang Y.-T., Hu Y.-M., Zhang Z.-Y., Li J.-X., other 3 authors Immunogenicity and safety of an enterovirus 71 vaccine in healthy Chinese children and infants: a randomised, double-blind, placebo-controlled phase 2 clinical trial. Lancet 2013, 381:1037-1045.
19. Li Y.-P., Liang Z.-L., Gao Q., Huang L.-R., Mao Q.-Y., Wen S.-Q., Liu Y., Yin W.-D., Li R.-C., Wang J.-Z. Safety and immunogenicity of a novel human enterovirus 71 (EV71) vaccine: a randomized, placebo-controlled, double-blind, phase I clinical trial. Vaccine 2012, 30:3295-3303.
20. Mao Q.Y., Li N., Yu X., Yao X., Li F.X., Lu F.M., Zhuang H., Liang Z.L., Wang J.Z. Antigenicity, animal protective effect and genetic characteristics of candidate vaccine strains of enterovirus 71. Arch. Virol. 2012, 157:37-41.
21. Cheng A., Fung C.P., Liu C.C., Lin Y.T., Tsai H.Y., Chang S.C., Chou A.H., Chang J.Y., Jiang R.H., Hsieh Y.C., other 3 authors Aphase I, randomized, open-label study to evaluate the safety and immunogenicity of an enterovirus 71 vaccine. Vaccine 2013, 31:2471-2476.
22. Mateu M.G. Antibody recognition of picornaviruses and escape from neutralization: a structural view. Virus Res. 1995, 38:1-24.
23. Noad R., Roy P. Virus-like particles as immunogens. Trends Microbiol. 2003, 11:438-444.
24. Ramqvist T., Andreasson K., Dalianis T. Vaccination, immune and gene therapy based on virus-like particles against viral infections and cancer. Expert Opin. Biol. Ther. 2007, 7:997-1007.
25. Hu Y.-C., Hsu T.-A., Huang J.-H., Ho M.-S., Ho Y.-C. Formation of enterovirus-like particle aggregates by recombinant baculoviruses co-expressing P1 and 3CD in insect cells. Biotechnol. Lett. 2003, 25:919-925.
26. Chung Y.-C., Huang J.-H., Lai C.-W., Sheng H.-C., Shih S.-R., Ho M.-S., Hu Y.-C. Expression, purification and characterization of enterovirus 71 virus-like particles. World J. Gastroenterol. 2006, 12:921-927.
27. O'Reilly D., Miller L., Luckow V. Baculovirus expression vectors: a laboratory manual 1992, W.H. Freeman and Co, New York.
28. Chung C.Y., Chen C.Y., Lin S.Y., Chung Y.C., Chiu H.Y., Chi W.K., Lin Y.L., Chiang B.L., Chen W.J., Hu Y.C. Enterovirus 71 virus-like particle vaccine: improved production conditions for enhanced yield. Vaccine 2010, 28:6951-6957.
29. Diminsky D., Moav N., Gorecki M., Barenholz Y. Physical, chemical and immunological stability of CHO-derived hepatitis B surface antigen (HBsAg) particles. Vaccine 1999, 18:3-17.
30. Shi L., Sanyal G., Ni A., Luo Z., Doshna S., Wang B., Graham T.L., Wang N., Volkin D.B. Stabilization of human papillomavirus virus-like particles by non-ionic surfactants. J.Pharm. Sci. 2005, 94:1538-1551.
31. Roldão A., Mellado M.C.M., Castilho L.R., Carrondo M.J.T., Alves P.M. Virus-like particles in vaccine development. Exp. Rev. Vaccines 2010, 9:1149-1176.
32. Peixoto C., Sousa M.F.Q., Silva A.C., Carrondo M.J.T., Alves P.M. Downstream processing of triple layered rotavirus like particles. J.Biotechnol. 2007, 127:452-461.
33. Ausar S.F., Foubert T.R., Hudson M.H., Vedvick T.S., Middaugh C.R. Conformational stability and disassembly of Norwalk virus-like particles. Effect of pH and temperature. J.Biol. Chem. 2006, 281:19478-19488.
34. Zhao Q., Allen M.J., Wang Y., Wang B., Wang N., Shi L., Sitrin R.D. Disassembly and reassembly improves morphology and thermal stability of human papillomavirus type 16 virus-like particles. Nanomedicine 2012, 8:1182-1189.
35. Le Tallec D., Doucet D., Elouahabi A., Harvengt P., Deschuyteneer M., Deschamps M. Cervarix, the GSK HPV-16/HPV-18 AS04-adjuvanted cervical cancer vaccine, demonstrates stability upon long-term storage and under simulated cold chain break conditions. Hum. Vaccin. 2009, 5:467-474.
36. Fernandez E., Toledo J.R., Mendez L., Gonzalez N., Parra F., Martin-Alonso J.M., Limonta M., Sanchez K., Cabrales A., Estrada M.P., Rodriguez-Mallon A., Farnos O. Conformational and thermal stability improvements for the large-scale production of yeast-derived rabbit hemorrhagic disease virus-like particles as multipurpose vaccine. PLoS One 2013, 8:e56417.
37. Shank-Retzlaff M.L., Zhao Q., Anderson C., Hamm M., High K., Nguyen M., Wang F., Wang N., Wang B., Wang Y., other 3 authors Evaluation of the thermal stability of Gardasil. Hum. Vaccin. 2006, 2:147-154.
38. Fiedler J.D., Higginson C., Hovlid M.L., Kislukhin A.A., Castillejos A., Manzenrieder F., Campbell M.G., Voss N.R., Potter C.S., Carragher B., Finn M.G. Engineered mutations change the structure and stability of a virus-like particle. Biomacromolecules 2012, 13:2339-2348.